Compare HROW & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | BVS |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 892.4M |
| IPO Year | 2008 | 2016 |
| Metric | HROW | BVS |
|---|---|---|
| Price | $28.43 | $14.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $65.00 | $17.60 |
| AVG Volume (30 Days) | ★ 550.4K | 362.4K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 71.43 | ★ 163.46 |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $568,087,000.00 |
| Revenue This Year | $28.59 | $6.46 |
| Revenue Next Year | $53.17 | $6.74 |
| P/E Ratio | ★ N/A | $28.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.96 | $6.47 |
| 52 Week High | $54.98 | $15.89 |
| Indicator | HROW | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 65.89 |
| Support Level | $26.96 | $12.43 |
| Resistance Level | $35.87 | $15.89 |
| Average True Range (ATR) | 1.41 | 0.49 |
| MACD | 0.19 | 0.19 |
| Stochastic Oscillator | 36.39 | 96.12 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.